SYS6010, epidermal growth factor receptor-targeting antibody-drug conjugate for advanced non-small cell lung cancer: A phase 1 trial.
Cancer CellAug 13, 2026 (epub)
Clinical ResearchOncology (Medical)
Zi-Ming Li, Zhen Zhou, Zhi-Yong He et al.
✦ AI-curated · Sources linked
In 30 seconds
This phase 1 trial evaluated SYS6010, an antibody-drug conjugate targeting EGFR, in 236 patients with advanced non-small cell lung cancer (NSCLC). The study found a manageable safety profile with treatment-related adverse events occurring in 99.6% of patients. The objective response rate was 34.7% in EGFR-mutant NSCLC treated with EGFR TKIs and platinum chemotherapy.
Key findings
- One dose-limiting toxicity occurred at 6.4 mg/kg, leading to cohort expansions at 4.2, 4.5, and 4.8 mg/kg.
- Treatment-related adverse events occurred in 99.6% of patients, with 57.2% experiencing grade ≥3 events.
- The objective response rate was 34.7% in EGFR-mutant NSCLC treated with EGFR TKIs and platinum chemotherapy.
- Median progression-free survival was 7.6 months and overall survival was 19.4 months in EGFR-mutant NSCLC.
Why it matters
The findings suggest that SYS6010 may provide a new treatment option for patients with advanced NSCLC, particularly those with EGFR mutations, highlighting its potential efficacy and safety profile in a challenging patient population.